Musculoskeletal diseases such as osteoarthritis,
osteoporosis and sarcopenia lead to an increasing global health burden. Marine
collagen peptides (MCPs) are the most promising candidate for nutritional
intervention and have significant advantages compared to their terrestrial
counterparts in terms of bioavailability, immunogenicity, and sustainable
exploitation using fish by-products. This chapter provides an overview of
published scientific evidence on the efficacy and modes of action of M CPs for
musculoskeletal health. Based on preclinical studies, done mostly in animal and
in vitro models, marine collagen can prevent the progression of osteoarthritis,
increase bone mineral density, and promote differentiation of osteoblasts. The
underlying mechanisms were related to the suppression of pro-inflammatory and
catabolic factors, such as matrix metalloproteinase-13 (MMP-13, interleukin-6
(IL-6) and promotion of anabolic genes, collagen type II alpha 1 chain
(COL2A1). Nevertheless, the clinical evidence is limited, and there is an
urgent requirement for more large RCTs (randomised controlled trials) of
long-term to confirm these preclinical findings for the human population. In
addition, there are substantial voids related to dose-response effects,
comparative effectiveness across marine sources, and sequence-specific
bioactive peptide sequences. Standardisation of product quality, purity and
contaminant screening is a key obstacle within the field to clinical
translation and public confidence. This chapter includes a review of the
literature, identifies key gaps in research, and provides recommendations to
advance the science to fully realise the therapeutic potential of marine
collagen peptides for musculoskeletal health.
Author(s) Details
A. A. Zubair
PG and Research Department of Aquaculture and Fishery Microbiology, MES
Ponnani College, India.
Please see the book here :- https://doi.org/10.9734/bpi/rpbs/v10/7243
No comments:
Post a Comment